Cook Research initiates RCT for Evero DCB in PAD treatment
The Evero drug-coated balloon is being evaluated for long-term safety and effectiveness against paclitaxel DCBs in PAD.
Indication
Clinical and regulatory intelligence for Peripheral Arterial Disease with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.